Revenue Growth (YoY)

Zimmer Biomet's current revenue growth of 9.3% year-over-year (YoY) means that the company's sales in its most recent fiscal period were 9.3% higher than the same period one year earlier — a measure of top-line expansion.

This rate sits above the sector median of 6.2%, placing Zimmer Biomet in the 62nd percentile among healthcare peers, indicating it is outperforming a majority of comparable companies on this metric. However, the trend data is not available: the year-over-year change, quarter-over-quarter change, and the direction over the last eight quarters are all marked as N/A, with only a single historical value of 9.3% provided. Without a multi-period trend, the current level alone offers limited insight into momentum or sustainability, making it difficult to assess whether this growth is accelerating or decelerating. The combination of a relatively strong level with no trend data implies moderate opportunity from the current outperformance, but also introduces uncertainty about future consistency — neither a clear risk nor a clear reward signal. This metric supports the overall NEUTRAL verdict, as the single data point does not provide enough directional evidence to shift the view from neutral.

Frequently Asked Questions

Closest Sector Peers